Skip to main content

Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

User login

Username

Password

Reset your password

Type	Lead	score